Novo Settles Ozempic Patent Fight With Three More Generic Makers

Novo Nordisk A/S settled a patent lawsuit and related validity challenge over copies of its blockbuster weight-loss and diabetes drug Ozempic with generic pharmaceutical companies Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., and Apotex Inc.

The companies requested the Patent Trial and Appeal Board to terminate the three generic drugamakers’ challenge to Novo US Patent No. 10,335,462 in motions filed Monday and Tuesday, days after Novo’s settlement with Mylan Pharmaceuticals Inc. in a dispute centered on the same patent was announced. Settlement details haven’t been made public.

After Novo sued numerous generic drugmakers in 2022 over alleged ...